(Q43607483)

English

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). (English)

1 reference

Europe PubMed Central

25 November 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Michael Lauseker

5

1 reference

Europe PubMed Central

25 November 2017

Andreas Hochhaus

32

1 reference

Europe PubMed Central

25 November 2017

Claudia Haferlach

8

object named as

C Haferlach

1 reference

Europe PubMed Central

25 November 2017

26

object named as

T P Hughes

1 reference

Europe PubMed Central

25 November 2017

author name string

B Hanfstein

1

1 reference

Europe PubMed Central

25 November 2017

M C Müller

2

1 reference

Europe PubMed Central

25 November 2017

R Hehlmann

3

1 reference

Europe PubMed Central

25 November 2017

P Erben

4

1 reference

Europe PubMed Central

25 November 2017

A Fabarius

6

1 reference

Europe PubMed Central

25 November 2017

S Schnittger

7

1 reference

Europe PubMed Central

25 November 2017

G Göhring

9

1 reference

Europe PubMed Central

25 November 2017

U Proetel

10

1 reference

Europe PubMed Central

25 November 2017

H-J Kolb

11

1 reference

Europe PubMed Central

25 November 2017

S W Krause

12

1 reference

Europe PubMed Central

25 November 2017

W-K Hofmann

13

1 reference

Europe PubMed Central

25 November 2017

J Schubert

14

1 reference

Europe PubMed Central

25 November 2017

H Einsele

15

1 reference

Europe PubMed Central

25 November 2017

J Dengler

16

1 reference

Europe PubMed Central

25 November 2017

M Hänel

17

1 reference

Europe PubMed Central

25 November 2017

C Falge

18

1 reference

Europe PubMed Central

25 November 2017

L Kanz

19

1 reference

Europe PubMed Central

25 November 2017

A Neubauer

20

1 reference

Europe PubMed Central

25 November 2017

M Kneba

21

1 reference

Europe PubMed Central

25 November 2017

F Stegelmann

22

1 reference

Europe PubMed Central

25 November 2017

M Pfreundschuh

23

1 reference

Europe PubMed Central

25 November 2017

C F Waller

24

1 reference

Europe PubMed Central

25 November 2017

S Branford

25

1 reference

Europe PubMed Central

25 November 2017

K Spiekermann

27

1 reference

Europe PubMed Central

25 November 2017

G M Baerlocher

28

1 reference

Europe PubMed Central

25 November 2017

M Pfirrmann

29

1 reference

Europe PubMed Central

25 November 2017

J Hasford

30

1 reference

Europe PubMed Central

25 November 2017

S Saußele

31

1 reference

Europe PubMed Central

25 November 2017

SAKK

33

1 reference

Europe PubMed Central

25 November 2017

German CML Study Group

34

1 reference

Europe PubMed Central

25 November 2017

publication date

26 March 2012

1 reference

Europe PubMed Central

25 November 2017

1 reference

Europe PubMed Central

25 November 2017

26

1 reference

Europe PubMed Central

25 November 2017

9

1 reference

Europe PubMed Central

25 November 2017

2096-2102

1 reference

Europe PubMed Central

25 November 2017

https://scigraph.springernature.com/pub.10.1038/leu.2012.85

0 references

Chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Harmonization of molecular monitoring of CML therapy in Europe

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Standardisation of molecular monitoring for chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.85

21 January 2018

Identifiers

10.1038/LEU.2012.85

1 reference

Europe PubMed Central

25 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43607483&oldid=2101868168"